Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel.
Zambetti, M.; Mariani, G.; Demicheli, R.; Verderio, P.; Potepan, P., and Garbagnati, F. Breast Cancer Research & Treatment. 62(2):135-139, 2000 Jul.

Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer.
Zambelli, A.; della Cuna, F. S. R.; Ponchio, L.; Ucci, G.; Da Prada, G. A., and della CunaG. R.. Breast Cancer Research & Treatment. 61(3):241-247, 2000 Jun.

Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells.
Weaver, C. H.; Schulman, K. A.; Wilson-Relyea, B.; Birch, R.; West, W., and Buckner, C. D. Journal of Clinical Oncology. 18(1):43-53, 2000 Jan.

First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer.
Vici, P.; Amodio, A.; Di Lauro, L.; Conti, F.; Gionfra, T.; Belli, F., and Lopez, M. (Reprint available from: Vici P Ist Regina Elena Studio & Cura Tumori, Div Med Oncol 2 Viale Regina Elena 291 I-00161 Rome Italy). Oncology. 58(1):3-7, 2000.

Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin.
Venturino, A.; Comandini, D.; Simoni, C.; Merlini, L.; Naso, C.; Palumbo, R.; Fusco, V.; Porcile, G.; Pronzato, P.; Rosso, R., and Repetto, L. Breast Cancer Research& Treatment. 60(3):195-200, 2000 Apr.

Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
Venturini, M.; Lunardi, G.; Del Mastro, L.; Vannozzi, M. O.; Tolino, G.; Numico, G.; Viale, M.;Pastrone, I.;Angiolini, C.; Bertelli, G.; Straneo, M.; Rosso, R., and Esposito,M. Journal of Clinical Oncology. 18(10):2116-2125, 2000 May.

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Stadtmauer, E. A.; O'Neill, A.; Goldstein, L. J.; Crilley, P. A.; Mangan, K. F.; Ingle, J. N.; Brodsky, I.; Martino, S.; Lazarus, H. M.; Erban, J. K.; Sickles, C., and Glick, J. H. New England Journal of Medicine. 342(15):1069-1076, 2000 Apr 13.

Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulatin factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Sparano, J. A.; O'Neill, A.; Schaefer, P. L.; Falkson, C. I., and Wood, W. C. Journal of Clinical Oncology. 18(12):2369-2377, 2000 Jun.

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Saso, R.; Kulkarni, S.; Mitchell, P.; Treleaven, J.; Swansbury, G. J.; Mehta, J.; Powles, R.; Ashley, S.; Kuan, A., and Powles, T. (Reprint available from: Treleaven J Royal Marsden Hosp, Dept Haematol Downs Rd Sutton SM2 5PT Surrey England).. British Journal of Cancer. 83(1):91-94, 2000 Jul.

A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
Rischin, D.; Smith, J.; Millward, M.; Lewis, C.; Boyer, M.; Richardson, G.; Toner, G.; Gurney, H., and McKendrick, J. (Reprint available from: Rischin D Peter MacCallum Canc Inst, Div Haematol & Med Oncol 481 Little Lonsdale St Melbourne Vic 3000 Australia). British Journal of Cancer. 83(4):438-442, 2000 Aug.

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Pronk, L. C.; Vasey, P.; Sparreboom, A.; Reigner, B.; Planting, A. S. T.; Gordon, R. J.; Osterwalder, B.; Verweij, J., and Twelves, C. (Reprint available from: Pronk LC Univ Madrid, Hosp 12 Octubre, Med Oncol Serv Carretera Andalucia Km 5-4 E-28041 Madrid Spain). British Journal of Cancer. 83(1):22-29, 2000 Jul.

A unified definition of clinical anthracycline resistance breast cancer.
Pivot, X.; Asmar, L.; Buzdar, A. U.; Valero, V., and Hortobagyi, G. (Reprint available from: Pivot X Ctr Antoine Lacassagne 33 Ave Vallombrose Nice 2 France). British Journal of Cancer. 82(3):529-534, 2000 Feb.

Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial.
Perez- Manga, G.; Lluch, A.; Alba, E.; Moreno-Nogueira, J. A.; Palomero, M.; Garcia-Conde, J.; Khayat, D., and Rivelles, N. Journal of Clinical Oncology. 18(13):2545-2552, 2000 Jul.

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.
Perez, E. A.; Hillman, D. W.; Stella, P. J.; Krook, J. E.; Hartmann, L. C.; Fitch, T. R.; Hatfield, A. K.; Mailliard, J. A.; Nair, S.; Kardinal, C. G., and Ingle, J. N.. Cancer. 88(1):124-131, 2000 Jan 1.

Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
Patnaik, A.; MacKinnon, A.; Goss, P.; Nagy, T.; Stewart, K.; Keating, A., and Crump, M. Journal of Clinical Oncology. 18(12):2363-2368, 2000 Jun.

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer:
A European organization for research and treatment of cancer randomized study with cross-over.
Paridaens, R.; Biganzoli, L.; Bruning, P.; Klijn, J. G. M.; Gamucci, T.; Houston, S.; Coleman, R.; Schachter, J.; Van Vreckem, A.; Sylvester, R.; Awada, A.; Wildiers, J., and Piccart, M. Journal of Clinical Oncology. 18(4):724-733, 2000 Feb.

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
Norris, B.; Pritchard, K. I.; James, K.; Myles, J.; Bennett, K.; Marlin, S.; Skillings, J.; Findlay, B.; Vandenberg, T.; Goss, P.; Latreille, J.; Rudinskas, L.; Lofters, W.; Trudeau, M.; Osoba, D., and Rodgers, A. Journal of Clinical Oncology. 18(12):2385-2394, 2000 Jun.

Weekly schedule of vinorelbine in pretreated breast cancer patients.
Nistico, C.; Garufi, C.; Milella, M.; Vaccaro, A.; D'Ottavio, A. M.; Fabi, A.; Pace, A.; Bove, L.; Tropea, F.; Marsella, A.; Izzo, F.; D'Attino, R. M.; Ferraresi, V.; De Marco S, and Terzoli, E. Breast Cancer Research & Treatment. 59(3):223-229, 2000 Feb.

Evaluation of the predictive value of Her-2/neu overexpression and p53mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
Nieto, Y.; Cagnoni, P. J.; Nawaz, S.; Shpall, E. J.; Yerushalmi, R.; Cook, B.; Russell, P.; McDermit, J.; Murphy, J.; Bearman, S. I., and Jones, R. B.. Journal of Clinical Oncology. 18(10):2070-2080, 2000 May.

Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.
Nagourney, R. A.; Link, J. S.; Blitzer, J. B.; Forsthoff, C., and Evans, S. S.. Journal of Clinical Oncology. 18(11):2245-2249, 2000 Jun.

Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer [Review].
Nabholtz, J. M.; North, S.; Smylie, M.; Mackey, J.; Au, H. J.; Au, R.; Morrish, D.; Salter, E., and Tonkin, K. Seminars in Oncology. 27(2 Suppl 3):11-18, 2000 Apr.

Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy.
Marchioro, G.; Azzarello, G.; Viviani, F.; Barbato, F.; Pavanetto, M.; Rosetti, F.; Pappagallo, G. L., and Vinante, O. (Reprint available from: Vinante O Dipartimento Oncol Lgo S Giorgio 3 I-30033 Noale Italy).. Oncology. 59(2):100-104, 2000.

The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont.
Lam, P. B.; Vacek, P. M.; Geller, B. M., and Muss, H. B. Cancer. 89(2):369-375, 2000 Jul 15.

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
Lalisang, R. I.; Voest, E. E.; Wils, J. A.; Nortier, J. W.; Erdkamp, F. L.; Hillen, H. F.; Wals, J.;Schouten, H. C., and Blijham, G. H. (Reprint available from: Lalisang RI Maastricht Univ Hosp,Dept Internal Med POB 5800 NL-6202 AZ Maastricht Netherlands). British Journal of Cancer. 82(12):1914-1919, 2000 Jun.

Docetaxel-induced lymphopenia in patients with solid tumors - A prospective phenotypic analysis.
Kotsakis, A.; Sarra, E.; Peraki, M.; Koukourakis, M.; Apostolaki, S.; Souglakos, J.; Mavromanomakis, E.; Vlachonikolis, J., and Georgoulias, V. Cancer. 89(6):1380-1386, 2000 Sep 15.

Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.
Koc, O. N.; Gerson, S. L.; Cooper, B. W.; Dyhouse, S. M.; Haynesworth, S. E.; Caplan, A. I., and Lazarus, H. M. Journal of Clinical Oncology. 18(2):307-316, 2000 Jan.

Chemotherapy for breast carcinoma during pregnancy - A French national survey.
Giacalone, P. L.; Laffargue, F., and Benos, P. Cancer. 86(11):2266-2272, 1999 Dec 1.

Impairment of heart rate variability during paclitaxel therapy.
Ekholm, E. M. K.; Salminen, E. K.; Huikuri, H. V.; Jalonen, J.; Antila, K. J.; Salmi, T. A., and Rantanen, V. T. Cancer. 88(9):2149-2153, 2000 May 1.

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors.
Colleoni, M.; Bonetti, M.; Coates, A. S.; Castiglione-Gertsch, M.; Gelber, R. D.; Price, K.; Rudenstam, C. M.; Lindtner, J.; Collins, J.; Thurlimann, B.; Holmberg, S.; Veronesi, A.; Marini, G., and Goldhirsch, A.. Journal of Clinical Oncology. 18(3):584-590, 2000 Feb.

Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study.
Chaplain, G.; Milan, C.; Sgro, C.; Carli, P. M., and Bonithon-Kopp, C. Journal of Clinical Oncology. 18(15):2836-2842, 2000 Aug.

Cognitive function in breast cancer patients receiving adjuvant chemotherapy.
Brezden, C. B.; Phillips, K. A.; Abdolell, M.; Bunston, T., and Tannock, I. F. Journal of Clinical Oncology. 18(14):2695-2701, 2000 Jul.

Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin) [Review].
Burris, H. A. Seminars in Oncology. 27(2 Suppl 3):19-23, 2000 Apr.

Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer.
Bontenbal, M.; van Putten, W. L. J.; Burghouts, J. T. M.; Baggen, M. G. A.; Ras, G. J.; Stiegelis, W. F.; Beudeker, M.; Janssen, J. T. P.; Braun, J. J.; van der Linden, G. H. M.; van, d. e. r. Velden PC; van Geel, A. N.; Helle, P.; Leisink, M.; Foekens, J. A., and Klijn, J. G. M.. Journal of Clinical Oncology. 18(4):734-742, 2000 Feb.

High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer - Reply.
Stadtmauer, E. A.; Goldstein, L. J., and Glick, J. H. (Reprint available from: Stadtmauer EA Univ Penn, Ctr Canc Philadelphia, PA 19104 USA). New England Journal of Medicine. 343(6):440-441, 2000 Aug 10.

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
Rivera, E.; Holmes, F. A.; Frye, D.; Valero, V.; Theriault, R. L.; Booser, D.; Walters, R.; Buzdar, A. U.; Dhingra, K.; Fraschini, G., and Hortobagyi, G. N.. Cancer. 89(11):2195-2201, 2000 Dec 1.

State-of-the-art chemotherapy for advanced breast cancer [Review].
Piccart, M. J. and Awada, A. Seminars in Oncology. 27(5 Suppl 9):3-12, 2000 Oct. IN PROCESS Re:

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
Pedrazzoli, P.; Bianchi, A. S.; Renga, M., and Siena, S. (Reprint available from: Pedrazzoli P Osped Niguarda Ca Granda, Div Oncol Med Falck, Dipartimento Oncol Ematol Piazza Osped Maggiore 3 I-20162 Milan Italy). Journal of the National Cancer Institute. 92(15):1271-1272, 2000 Aug 2.

High-dose chemo for breast cancer: Does it still have a chance?
McNeil, C. Journal of the National Cancer Institute. 92(12):961-962, 2000 Jun 21. No abstract

Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors. Lokich, J. Cancer. 89(11):2309-2314, 2000 Dec 1. In process

Doxorubicin and paclitaxel in advanced breast carcinoma - Importance of prior adjuvant anthracycline therapy.
Lluch, A.; Ojeda, B.; Colomer, R.; Barnadas, A.; Massuti, B.; Casado, A.; Angeles, C., and Maroto, P. Cancer. 89(11):2169-2175, 2000 Dec 1.

High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer
Lippman, M. E. (Reprint available from: Lippman ME Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr Washington, DC 20007 USA). New England Journal of Medicine. 342(15):1119-1120, 2000 Apr 13. No abstract

Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Kwasny, W.; Kornek, G.; Haider, K.; Valencak, J.; Ulrich-Pur, H.; Penz, M.; Lang, F.; Depisch, D., and Scheithauer, W.. Breast Cancer Research & Treatment. 63(3):235-241, 2000 Oct.

Dose-dense chemotherapy for breast cancer: the story so far.
Hudis, C. (Reprint available from: Hudis C Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv 1275 York Ave New York, NY 10021 USA).. British Journal of Cancer. 82(12):1897-1899, 2000 Jun. No abstract

Vinorelbine - a clinical review [Review].
Gregory, R. K. and Smith, I. E. (Reprint available from: Smith IE Royal Marsden NHS Trust, Dept Med Fulham Rd London SW3 6JJ England). British Journal of Cancer. 82(12):1907-1913, 2000 Jun. No abstract

Scientific misconduct in a breast-cancer chemotherapy trial: response of University of the Witwatersrand.
Cleaton-Jones, P. (Reprint available from: Cleaton-Jones P Univ Witwatersrand, Comm Res Human Subjects Med Private Bag 3 ZA-2050 Wits South Africa). Lancet. 355(9208):1011-1012, 2000 Mar 18. No abstract

Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
Chang, J.; Ormerod, M.; Powles, T. J.; Allred, D. C.; Ashley, S. E., and Dowsett, M.. Cancer. 89(11):2145-2152, 2000 Dec 1.

Top of Page